The cytosine arabinoside cytarabine is an effective marine-derived antineoplastic agent for the treatment of acute myelogrnous and lymphocytic leukemias. As this nucleoside antimetabolite is an S-phase-specific drug, prolonged exposure of cells to toxic concentrations is critical to achieve maximum biological effect. The activity of cytarabine is nevertheless decreased by its rapid deamination to the biologically inactive metabolite uracil arabinoside. This rapid degradation process is the reason for the ongoing search for efficient formulations and derivatives of cytarabine that cannot be deaminated and exhibited better pharmacokinetic parameters. In the present study, pegylated liposomes were modified for intended prolonged delivery of ...
The systemic efficacy of the chemotherapeutic agents presently used to treat solid tumors is limited...
Cytarabine is widely used in chemotherapy for different types of leukemia due to the targeting effec...
Toxicity is a major limitation in clinical use of most anticancer drugs. Liposomes, especially targe...
Cancer is the second leading cause of death worldwide. The main modality to fight against cancer is ...
Importance of the field: Cytarabine is a polar nucleoside drug used for the treatment of myeloid leu...
International audienceAbstract CPX-351 is a liposomal form encapsulating cytarabine and daunorubicin...
Cancer is a life-threatening disease contributing to ~3.4 million deaths worldwide. There are variou...
Liposomes, which are vesicles composed of a phospholipid bilayer surrounding an aqueous milieu, repr...
Improving existing therapies with lipid based carriers has been successfully applied to drugs that h...
Background: CPX-351, a liposomal formulation of cytarabine and daunorubicin co-encapsulated at an op...
Cytarabine is an intravenous chemotherapeutic agent that is commonly used for treatment of white blo...
Most current anticancer agents present lack of specificity, leading to systemic toxicity and adverse...
Most current anticancer agents are present lack of specificity, leading to systemic toxicity and adv...
Objective: To investigate the pharmacokinetics and pharmacodynamics of liposomal daunombicin (DaunoX...
Background: Identification of effective systemic antineoplastic drugs against anaplastic thyroid car...
The systemic efficacy of the chemotherapeutic agents presently used to treat solid tumors is limited...
Cytarabine is widely used in chemotherapy for different types of leukemia due to the targeting effec...
Toxicity is a major limitation in clinical use of most anticancer drugs. Liposomes, especially targe...
Cancer is the second leading cause of death worldwide. The main modality to fight against cancer is ...
Importance of the field: Cytarabine is a polar nucleoside drug used for the treatment of myeloid leu...
International audienceAbstract CPX-351 is a liposomal form encapsulating cytarabine and daunorubicin...
Cancer is a life-threatening disease contributing to ~3.4 million deaths worldwide. There are variou...
Liposomes, which are vesicles composed of a phospholipid bilayer surrounding an aqueous milieu, repr...
Improving existing therapies with lipid based carriers has been successfully applied to drugs that h...
Background: CPX-351, a liposomal formulation of cytarabine and daunorubicin co-encapsulated at an op...
Cytarabine is an intravenous chemotherapeutic agent that is commonly used for treatment of white blo...
Most current anticancer agents present lack of specificity, leading to systemic toxicity and adverse...
Most current anticancer agents are present lack of specificity, leading to systemic toxicity and adv...
Objective: To investigate the pharmacokinetics and pharmacodynamics of liposomal daunombicin (DaunoX...
Background: Identification of effective systemic antineoplastic drugs against anaplastic thyroid car...
The systemic efficacy of the chemotherapeutic agents presently used to treat solid tumors is limited...
Cytarabine is widely used in chemotherapy for different types of leukemia due to the targeting effec...
Toxicity is a major limitation in clinical use of most anticancer drugs. Liposomes, especially targe...